October 19, 2021
A combination therapy pairing Eisai’s multikinase inhibitor Lenvima (lenvatinib) and MSD’s PD-1 inhibitor Keytruda (pembrolizumab) has won the backing of a key European panel for two indications related to renal cell carcinoma (RCC) and endometrial carcinoma. The European Medicines Agency’s...read more